The genetically modified genes of targeted protein ligands, including human epidermal growth factor (hEGF) and anti-HER2 Affibody, were introduced into cells to collect CMVs which presented tumor-targeting ligands on the membrane. The gene discussed is ERBB2; the disease is neoplasm.